Product Name: Ataxin3 Antibody
Species Reactivity: Human
Tested Applications: IHC-P
Applications: For IHC-P starting dilution is: 1:50~100
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 42 kDa
Immunogen: This Ataxin3 (MJD) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 29-59 amino acids from the N-terminal region of human Ataxin3 (MJD).
Host Species: Rabbit
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Physical State: Liquid
CAS NO.: 1643913-93-2
Product: PAK4-IN-1
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 1.14 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Ataxin-3, Machado-Joseph disease protein 1, Spinocerebellar ataxia type 3 protein, ATXN3, ATX3, MJD, MJD1, SCA3
Accession NO.: P54252
Protein Ino: 290457685
Official Symbol: ATXN3
Geneid: 4287
Background: Machado-Joseph disease is an autosomal dominant neurologic disorder, and is now known to be the same as previously described spinocerebellar ataxia-3. MJD protein (Ataxin-3) contains (CAG)n repeats in the coding region, and the expansion of these repeats from the normal 13-36 to 68-79 is the cause of Machado-Joseph disease. There is a negative correlation between the age of onset and CAG repeat numbers. This protein interacts with key regulators (CBP, p300 and PCAF) of transcription and represses transcription, and also acts as a histone-binding protein that regulates transcription. MJD is a deubiquitinating enzyme.
PubMed ID:http://aac.asm.org/content/53/6/2444.abstract
